A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Completed · Phase 1/Phase 2
Conditions studied: Mantle-Cell Lymphoma
In brief
Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib. Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for patients with mantle cell lymphoma who have received at least one prior therapy. Ixazomib is in a class of medications called proteasome inhibitors. Cancer cells depend on proteasome to provide this protein metabolism (turnover) function to regulate their growth and survival. Ixazomib disrupts a cancer cells' ability to survive by blocking the proteasome and disrupting protein metabolism. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory MCL and to examine the side effects associated with ixazomib in combination with ibrutinib.
Key facts
- Study ID
- NCT03323151
- Run by
- PrECOG, LLC.
- People needed
- 43
- Starts
- 2018-08-13
- Expected to finish
- 2023-09-07
- Last updated by the study team
- 2026-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- Georgia Cancer Center at Augusta University — Augusta, Georgia, United States
- Carle Cancer Center — Urbana, Illinois, United States
- University of Kansas — Overland Park, Kansas, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Laura and Isaac Perlmutter Cancer Center at NYU — New York, New York, United States
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania, United States
- University of Virginia — Charlottesville, Virginia, United States
- West Virginia University — Morgantown, West Virginia, United States
- Gundersen Health System — La Crosse, Wisconsin, United States
- University of Wisconsin — Madison, Wisconsin, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- ProHealth Care — Waukesha, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.